1 | Abatacept | Abatacept 36件: Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (ctla4-ig); Abatacept (iv); Abatacept (sc); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept active treatment; Abatacept delayed-onset treatment; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Device: abatacept combination product (acp); Double-blind abatacept; Drug: abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Orencia® (abatacept); Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | 1件: D03203 D03203 💬 |
2件: CD80, CD86 💬 |
Allograft rejection 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
2 | Acyclovir | Acyclovir 1件: Acyclovir; | 1件: D00222 D00222 💬 |
- |
- |
013 5件: 13, 28, 46, 53, 60 💬 |
3 | Alginic acid | Alginic acid 1件: Alginic acid; | 1件: D02324 D02324 💬 |
- |
- |
051 3件: 51, 53, 299 💬 |
4 | Aloe Vera Leaf | - | - |
- |
- |
053 2件: 53, 97 💬 |
5 | Aminohippuric acid | - | 2件: D01421 D01421
D06890 D06890 💬 |
- |
- |
049 4件: 49, 53, 67, 86 💬 |
6 | Artesunate | Artesunate 1件: Artesunate; | 1件: D02482 D02482 💬 |
- |
- |
046 7件: 46, 53, 66, 96, 97, 215, 271 💬 |
7 | Baminercept | Baminercept 3件: Baminercept; Baminercept alfa; Baminercept alfa (bg9924); | 1件: D08866 D08866 💬 |
1件: LTB 💬 |
Cytokine-cytokine receptor interaction 3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
013 4件: 13, 46, 53, 97 💬 |
8 | Belimumab | Belimumab 26件: Belimumab; Belimumab 1 mg/kg; Belimumab 10 mg; Belimumab 10 mg/kg; Belimumab 10 mg/kg plus standard therapy; Belimumab 100 mg sc; Belimumab 10mg/kg; Belimumab 200 mg sc; Belimumab 200 mg/ml; Belimumab 4 mg/kg; Belimumab for iv; Belimumab for sc; Belimumab injection; Belimumab injection [benlysta]; Belimumab or benlysta; Belimumab plus early vaccination; Belimumab plus late vaccination; Benlysta (belimumab); Benlysta? (belimumab); Benlysta® (belimumab); Benlysta™ (belimumab); Combination product: belimumab; Device: belimumab autoinjector; Gsk1550188 (belimumab); Prednisone and belimumab; Sc belimumab 200 mg; | 1件: D03068 D03068 💬 |
1件: TNFSF13B 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
011 10件: 11, 43, 44, 46, 49, 51, 53, 66, 222, 300 💬 |
9 | BMS-986142 | Bms-986142 6件: Bms-986142; Bms-986142 200mg; Bms-986142 350mg; Bms986142; Methotrexate, leucovorin and bms-986142; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; | - |
- |
- |
046 3件: 46, 53, 160 💬 |
10 | Boscalid | - | - |
- |
- |
053 1件: 53 💬 |
11 | Branebrutinib | Branebrutinib 1件: Branebrutinib; | 1件: D11478 D11478 💬 |
1件: BTK 💬 |
B cell receptor signaling pathway 7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency |
046 3件: 46, 49, 53 💬 |
12 | Bupivacaine | Bupivacaine 10件: Bupivacaine; Bupivacaine hydrochloride; Bupivacaine hydrochloride 0.5% (marcaine, pfizer); Bupivacaine injection 0.5%; Bupivacaine/epinephrine/dexamethasone; Ercp with bupivacaine infusion; Lap tap bupivacaine/epinephrine; Levobupivacaine; Liposomal bupivacaine; Us tap bupivacaine/epinephrine; | 2件: D01450 D01450
D07552 D07552 💬 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
046 8件: 46, 51, 53, 70, 96, 168, 226, 298 💬 |
13 | Calcium | Amorphous calcium carbonate 34件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium and vitamin d combination; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium carbonate d; Calcium channel blockers; Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ethylhydrogenfumarat, calciumsalz; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Other: calcium stable isotope; Other: determination of calcium intake by a dietician interview; Other: empiric use of calcium carbonate and calcitriol; Other: pth based calcium carbonate and calcitriol repletion; Other: serum calcium concentrations results; Rosuvastatin calcium; Rosuvastatin calcium 40mg; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; Vidofludimus calcium dihydrate; | - |
- |
- |
006 27件: 6 , 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬 |
14 | Calcium carbonate | Amorphous calcium carbonate 6件: Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium carbonate d; Other: empiric use of calcium carbonate and calcitriol; Other: pth based calcium carbonate and calcitriol repletion; | 2件: D00932 D00932
D10802 D10802 💬 |
- |
- |
013 8件: 13, 19, 46, 53, 75, 96, 235, 299 💬 |
15 | Carbomer | Carbomer 2件: Carbomer; Carbomer 974p; | - |
- |
- |
053 1件: 53 💬 |
16 | Carbon monoxide | Carbon monoxide 3件: Carbon monoxide; Inhaled carbon monoxide; Other: carbon monoxide-bubbled mediums; | 1件: D09706 D09706 💬 |
- |
- |
006 7件: 6 , 13, 53, 70, 85, 86, 298 💬 |
17 | Carbonate ion | - | - |
- |
- |
002 12件: 2 , 13, 17, 18, 19, 46, 53, 75, 96, 127, 235, 299 💬 |
18 | Carbopol 974P | - | - |
- |
- |
053 1件: 53 💬 |
19 | Cevimeline | Cevimeline 1件: Cevimeline; | 2件: D00661 D00661
D07667 D07667 💬 |
1件: CHRM3 💬 |
Alzheimer disease 11件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
053 1件: 53 💬 |
20 | Chloride ion | - | - |
- |
- |
006 25件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
21 | Cholecalciferol | 5000 iu of cholecalciferol 11件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol (vitamind3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol concentrate (water-dispersible form); Cholecalciferol, vitamin d3; | 1件: D00188 D00188 💬 |
1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 23件: 6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 162, 202, 228, 271, 298, 299 💬 |
22 | Citric acid | Citric acid 3件: Citric acid; Citric acid based mouthwash; Sodium picosulfate, magnesium oxide and citric acid; | 2件: D00037 D00037
D01222 D01222 💬 |
- |
- |
053 2件: 53, 291 💬 |
23 | Coconut | Coconut 4件: Coconut; Coconut oil; Coconut oil and epigallocatechin gallate; Other: natural herbs of coconut, aloe vera, and pepperint; | - |
- |
- |
013 2件: 13, 53 💬 |
24 | Cyclosporine | Atg+cyclosporine 26件: Atg+cyclosporine; Atg+rapamune+cyclosporine; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide,cyclosporine a; Cyclosporine; Cyclosporine (gengraf ); Cyclosporine (usan); Cyclosporine 5 mg/kg bid days 0-14; Cyclosporine a; Cyclosporine a (csa); Cyclosporine a dry powder inhalation (drug); Cyclosporine combine with mycophenolate mofetil; Cyclosporine inhalation solution; Cyclosporine inhalation solution (cis); Cyclosporine oral product; Cyclosporine pill; Cyclosporine vs infliximab; Cyclosporine-a; Device: cyclosporine a; Liposomal aerosol cyclosporine; Liposomal cyclosporine a; Liposomal cyclosporine a 10 mg; Liposomal cyclosporine a 5 mg; Oral cyclosporine; Rabbit atg, cyclosporine, levamisole; Twice-daily dosage with 0.5% cyclosporine-a eyedrops; | 1件: D00184 D00184 💬 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬 |
25 | Dexamethasone | Bortezomib/dexamethasone 48件: Bortezomib/dexamethasone; Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, and dexamethasone (cybord); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Device: dexamethasone injection; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,1 mg tablets; Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in mucolox™; Dexamethasone 1,5 mg tablets; Dexamethasone 21-dihydrogen phosphate; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone 4 mg jenapharm; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone oral tablet 8mg (dexamethasone krka tablets(8mg), warsaw, poland).; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone sodium sulfate; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; Diagnostic test: dexamethasone test; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone; Procedure: epidural steroid (dexamethasone) injection; | 9件: D00292 D00292
D00975 D00975
D01510 D01510
D01615 D01615
D01632 D01632
D01948 D01948
D02174 D02174
D02591 D02591
D02592 D02592 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 162, 222, 235, 283, 296, 299 💬 |
26 | Diquafosol | Diquafosol 1件: Diquafosol; | - |
- |
- |
053 1件: 53 💬 |
27 | Dornase alfa | Dornase alfa 6件: Dornase alfa; Dornase alfa (pulmozyme); Dornase alfa [pulmozyme®]; Other: continuation of dornase alfa (dnase); Other: discontinuation of dornase alfa (dnase); Pulmozyme (dornase alfa); | 1件: D03896 D03896 💬 |
- |
- |
053 2件: 53, 299 💬 |
28 | Efalizumab | Efalizumab 1件: Efalizumab; | 1件: D03959 D03959 💬 |
1件: ITGAL 💬 |
Cell adhesion molecules 12件: Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
011 9件: 11, 13, 37, 46, 49, 53, 61, 95, 96 💬 |
29 | Estetrol | Estetrol 1件: Estetrol; | 2件: D11513 D11513
D11514 D11514 💬 |
2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
053 1件: 53 💬 |
30 | Etanercept | 50 mg etanercept 49件: 50 mg etanercept; Adalimuab, etanercept, tocilizumab, or abatacept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (etn); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg sc day 0 and day 3; Etanercept 50 mg/ml; Etanercept 50mg; Etanercept auto-injector; Etanercept biosimilar; Etanercept liquid; Etanercept optimal dosing; Etanercept or adalimumab; Etanercept pre-filled syringe; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Lyophilized etanercept powder(yisaipu); Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Prefilled liquid etanercept(yisaipu); Procedure: intra-articular injection of etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | 1件: D00742 D00742 💬 |
2件: LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
015 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 💬 |
31 | Filgotinib | Filgotinib 4件: Filgotinib; Inn - filgotinib; Proposed inn - filgotinib; Propsoed inn - filgotinib; | 1件: D10871 D10871 💬 |
1件: JAK1 💬 |
Coronavirus disease - COVID-19 27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 6件: 46, 53, 96, 97, 222, 271 💬 |
32 | Fludeoxyglucose (18F) | - | - |
- |
- |
005 13件: 5 , 6 , 7 , 13, 34, 41, 46, 53, 84, 85, 96, 127, 300 💬 |
33 | Gadoteric acid | Gadoteric acid 1件: Gadoteric acid; | 1件: D08007 D08007 💬 |
- |
- |
013 2件: 13, 53 💬 |
34 | Ginseng | American ginseng 4件: American ginseng; American ginseng extract ht-1001; Ginseng; Korean red ginseng; | 1件: D06772 D06772 💬 |
- |
- |
013 3件: 13, 46, 53 💬 |
35 | Glycyrrhiza glabra | Glycyrrhiza glabra 2件: Glycyrrhiza glabra; Glycyrrhiza glabra root; | - |
- |
- |
053 2件: 53, 97 💬 |
36 | Gold | Gold 7件: Gold; Gold nanocrystals; Mtx goldshield tablets; Other: comparator: cpet cycle ergometer (gold standard); Procedure: quantiferon-tb gold assay; Procedure: repair of cdh w/sis gold; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
002 38件: 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
37 | Human interleukin-2 | Anti-human interleukin-23 monoclonal antibody 3件: Anti-human interleukin-23 monoclonal antibody; Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
002 17件: 2 , 13, 35, 46, 49, 51, 53, 55, 56, 60, 63, 65, 95, 96, 97, 162, 271 💬 |
38 | Hyaluronic acid | Hyaluronic acid 5件: Hyaluronic acid; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid inhalation solution; Hyaluronic acid/chondroitin sulfate; Standard care hyaluronic acid eye drops; | 1件: D08043 D08043 💬 |
- |
- |
046 7件: 46, 53, 70, 97, 226, 231, 299 💬 |
39 | Hydrocortisone | 90 mg hydrocortisone acetate suppository with sephure suppository applicator 31件: 90 mg hydrocortisone acetate suppository with sephure suppository applicator; Combination oral budesonide and rectal hydrocortisone; Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortef (hydrocortisone); Dual release hydrocortisone (plenadren); Hydrocortisone; Hydrocortisone (solucortef); Hydrocortisone 100mg/ml; Hydrocortisone 10mg; Hydrocortisone 10mg tablet; Hydrocortisone 10mg tablets; Hydrocortisone 20mg tablets; Hydrocortisone acetate; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g fna fagron; Hydrocortisone hydrogen succinate; Hydrocortisone modified release capsules; Hydrocortisone roussel; Hydrocortisone sodium acetate; Hydrocortisone sodium phosphate; Hydrocortisone sodium succinate; Hydrocortisone tablet 2.5 mg; Hydrocortisone takeda, tabletter; Mesalazine with hydrocortisone sodium succinate; Other: hydrocortisone; Procedure: hydrocortisone withdrawal; Solu-cortef (hydrocortisone); Subcutaneous hydrocortisone; Subcutaneous hydrocortisone 10mg; | 1件: D00088 D00088 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 9件: 6 , 46, 53, 75, 78, 81, 83, 97, 299 💬 |
40 | Hydroxychloroquine | Hydroxychloroquine 19件: Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Other: hydroxychloroquine/chloroquine; Plaquenil - hydroxychloroquine 200mg film coated tablets; Sirolimus and hydroxychloroquine 200 mg; Sirolimus and hydroxychloroquine 400 mg; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | 1件: D08050 D08050 💬 |
- |
- |
013 23件: 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 218, 222, 234, 254, 271, 298, 299 💬 |
41 | Iguratimod | Iguratimod 2件: Iguratimod; Iguratimod (careram); | 1件: D01146 D01146 💬 |
1件: NFKB1 💬 |
AGE-RAGE signaling pathway in diabetic complications 72件: AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amoebiasis, Antifolate resistance, Apoptosis, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Chronic myeloid leukemia, Cocaine addiction, Coronavirus disease - COVID-19, Cytosolic DNA-sensing pathway, Diabetic cardiomyopathy, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Longevity regulating pathway, MAPK signaling pathway, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prolactin signaling pathway, Prostate cancer, RIG-I-like receptor signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway |
046 4件: 46, 51, 53, 271 💬 |
42 | Iscalimab | Cfz533 (iscalimab) 2件: Cfz533 (iscalimab); Iscalimab; | 1件: D11610 D11610 💬 |
1件: CD40 💬 |
Allograft rejection 16件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis |
049 2件: 49, 53 💬 |
43 | Lanraplenib | Lanraplenib 1件: Lanraplenib; | 1件: D11596 D11596 💬 |
- |
- |
053 2件: 53, 222 💬 |
44 | Leflunomide | Leflunomide 10件: Leflunomide; Leflunomide (permitted, not necessary); Leflunomide 10 milligram (mg); Leflunomide 10mg tab; Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Leflunomide 20mg tab; Leflunomide mylan; Leflunomide(lef); Leflunomide-sulfasalazine-hydroxychloroquine; | 1件: D00749 D00749 💬 |
1件: DHODH 💬 |
Biosynthesis of cofactors 3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism |
011 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 💬 |
45 | Leniolisib | Leniolisib 1件: Leniolisib; | 1件: D11158 D11158 💬 |
3件: PIK3CA, PIK3CB, PIK3CD 💬 |
AGE-RAGE signaling pathway in diabetic complications 103件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway |
053 2件: 53, 65 💬 |
46 | Levocarnitine | Levocarnitine 4件: Levocarnitine; Levocarnitine propyl hydrochloride; Valproate, levocarnitine; Valproic acid and levocarnitine; | 3件: D02030 D02030
D02176 D02176
D04713 D04713 💬 |
- |
- |
003 10件: 3 , 5 , 13, 53, 58, 96, 97, 265, 298, 316 💬 |
47 | Levofloxacin | Levofloxacin 4件: Levofloxacin; Levofloxacin hemihydrate; Levofloxacin kabi; Mp-376 (levofloxacin solution for inhalation); | 2件: D00588 D00588
D08120 D08120 💬 |
- |
- |
046 5件: 46, 53, 84, 85, 299 💬 |
48 | Licorice | Licorice 1件: Licorice; | 1件: D04365 D04365 💬 |
- |
- |
053 2件: 53, 83 💬 |
49 | Lulizumab pegol | Lulizumab pegol 1件: Lulizumab pegol; | - |
- |
- |
049 3件: 49, 53, 160 💬 |
50 | Meglumine | Meglumine 6件: Meglumine; Procedure: mri imaging with intravenous contrast with gadoterate meglumine; Tafamidis meglumine; Tafamidis meglumine 20 mg soft gelatin capsules; Tafamidis meglumine 20mg soft gelatin capsule (clinical trial image); Tafamidis meglumine 20mg soft gelatin capsule (commerical image); | 1件: D01796 D01796 💬 |
- |
- |
028 2件: 28, 53 💬 |
51 | Methotrexate | Abatacept (aba) + methotrexate (mtx), double-blind (db) 113件: Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Combination product: methotrexate; Cp-690,550 + methotrexate; Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Cyclosporin, methotrexate (gvhd prophylaxis); Dmards (methotrexate; Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate 'lederle' tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate (stable dose); Methotrexate (tapering dose); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 10 mg; Methotrexate 10 mg tablets; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate ``lederle`` 2.5mg tablets; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate ebewe; Methotrexate hospira 2,5 mg tablety; Methotrexate hospira 2.5 mg tablety; Methotrexate injection; Methotrexate lachema 5inj. sol; Methotrexate lederle 2.5 mg tablets; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate sodium tablets 2.5mg; Methotrexate tablets; Methotrexate tablets 2.5 mg; Methotrexate treatment; Methotrexate wyeth 2,5mg; Methotrexate wyeth 2,5mg tbl.; Methotrexate ® 2.5mg tablets; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol; Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate*10mg/1,33ml 4s; Methotrexate*15mg/2ml 4sir; Methotrexate*2,5mg 25cpr; Methotrexate*20mg/2,66ml 4s; Methotrexate*25cpr 2,5mg; Methotrexate*7,5mg/ml 4sir.; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Other: methotrexate therapy; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tak-715 and methotrexate; Tak-783 and methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab plus methotrexate; Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; | 2件: D00142 D00142
D02115 D02115 💬 |
2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
52 | Methylcellulose | - | 1件: D04996 D04996 💬 |
- |
- |
053 1件: 53 💬 |
53 | Methylprednisolone hemisuccinate | Methylprednisolone hemisuccinate 1件: Methylprednisolone hemisuccinate; | 1件: D05000 D05000 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 7件: 13, 49, 50, 51, 53, 97, 211 💬 |
54 | Microcrystalline cellulose | - | 1件: D00093 D00093 💬 |
- |
- |
035 4件: 35, 53, 96, 162 💬 |
55 | Mizoribine | Mizoribine 1件: Mizoribine; | 1件: D01392 D01392 💬 |
2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
046 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬 |
56 | Mycophenolate mofetil | Azathioprine or mycophenolate mofetil 19件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil; Prednisone, ciclosporin and mycophenolate mofetil; Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil); | 3件: D00752 D00752
D05094 D05094
D05095 D05095 💬 |
2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 32件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
57 | Mycophenolic acid | Mycophenolic acid 2件: Mycophenolic acid; Mycophenolic acid mofetil; | 1件: D05096 D05096 💬 |
2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 34件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
58 | NGX267 | Ngx267 1件: Ngx267; | - |
- |
- |
053 1件: 53 💬 |
59 | Nivolumab | Nivolumab 1件: Nivolumab; | 1件: D10316 D10316 💬 |
1件: PDCD1 💬 |
Cell adhesion molecules 3件: Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
013 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬 |
60 | Olea europaea leaf | - | - |
- |
- |
013 3件: 13, 49, 53 💬 |
61 | Olive oil | Freshly-pressed extra virgin olive oil 2件: Freshly-pressed extra virgin olive oil; Olive oil; | 1件: D03311 D03311 💬 |
- |
- |
013 4件: 13, 49, 53, 96 💬 |
62 | Omalizumab | Omalizumab 4件: Omalizumab; Omalizumab (xolair); Recombinant humanized monoclonal antibody omalizumab to ige; Rituximab combined with omalizumab; | 1件: D05251 D05251 💬 |
1件: FCER1A 💬 |
Asthma 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 7件: 46, 53, 65, 98, 162, 226, 299 💬 |
63 | Parsaclisib | Parsaclisib 1件: Parsaclisib; | 1件: D11437 D11437 💬 |
1件: PIK3CD 💬 |
AGE-RAGE signaling pathway in diabetic complications 103件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway |
035 3件: 35, 53, 61 💬 |
64 | Phosphate ion | - | - |
- |
- |
002 30件: 2 , 3 , 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 276, 283, 284, 285, 286, 299 💬 |
65 | Pilocarpine | Diagnostic test: iontophoresis sessions in forearm of subjects with pilocarpine 5件: Diagnostic test: iontophoresis sessions in forearm of subjects with pilocarpine; Pilocarpine; Pilocarpine hydrochloride; Pilocarpine nitrate 5%; Procedure: pilocarpine; | 3件: D00525 D00525
D02200 D02200
D05478 D05478 💬 |
2件: CHRM2, CHRM3 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 3件: 6 , 53, 299 💬 |
66 | Prasterone | Prasterone 2件: Prasterone; Prasterone (gl701); | 1件: D08409 D08409 💬 |
3件: AR, ESR1, ESR2 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
049 6件: 49, 53, 83, 86, 96, 113 💬 |
67 | Prednisone | 0 mg prednisone 73件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; Adalimumab, plus prednisone; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Enalapril valsartan methylprednisone; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Ir prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Methylprednisone; Mr prednisone; Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Other: prednisone; Over encapsulated prednisone; Prednisolone/prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 1 mg; Prednisone 15 mg; Prednisone 2 mg; Prednisone 3 mg; Prednisone 4 mg; Prednisone 5 mg; Prednisone 5 mg tablets; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and belimumab; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, ciclosporin and mycophenolate mofetil; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, low dose rituximab; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Procedure: thymectomy plus prednisone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Ursodeoxycholic acid+low dose glucocorticoid(prednisone); | 1件: D00473 D00473 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
68 | Rebamipide | Nanoparticulated rebamipide 3件: Nanoparticulated rebamipide; Other: autologous serum and rebamipide 2%; Rebamipide; | 1件: D01121 D01121 💬 |
- |
- |
046 4件: 46, 53, 97, 271 💬 |
69 | Rituximab | Abatacept, rituximab or tocilizumab 67件: Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Abp 798 biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Double-blind rituximab; Dr. reddy’s rituximab (drl_ri) 100mg; Dr. reddy’s rituximab (drl_ri) 500mg; Eltrombopag combining rituximab; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Prednisone, low dose rituximab; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (inn: rituximab), brand name in the us; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (eu); Rituximab (genetical recombination); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab (us); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Sait101 (rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab; [rituximab]; | 1件: D02994 D02994 💬 |
1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
011 47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
70 | Sodium chloride | 0.9% sodium chloride 24件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v isotonic sodium chloride solution; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Other: 0.9% sodium chloride; Other: 0.9ml sodium chloride; Other: sodium chloride; Physiological serum (sodium chloride); Procedure: 9% sodium chloride (nacl) iv; Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 0.9%; Sodium chloride 6%; Sodium chloride 7%; Sodium chloride ph. eur.; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; Solucion de cloruro de sodio sodium chloride solution; Solvente cloruro de sodio sodium chloride solvent; | 1件: D02056 D02056 💬 |
- |
- |
006 20件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
71 | Sulfate ion | - | - |
- |
- |
002 25件: 2 , 6 , 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 222, 226, 265, 296, 297, 299 💬 |
72 | Tacrolimus | Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf 17件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Rectal tacrolimus; Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil); Tacrolimus; Tacrolimus (advagraf); Tacrolimus (prograf®); Tacrolimus (tacro); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsule (low-dose); Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus tablets; Tacrolimus with methotrexate; | 2件: D00107 D00107
D08556 D08556 💬 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 32件: 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
73 | Tetracycline | Amoxicillin and tetracycline 4件: Amoxicillin and tetracycline; Amoxicillin, metronidazole and tetracycline; Tetracycline; Tetracycline - statin - antimycotic; | 1件: D00201 D00201 💬 |
- |
- |
013 5件: 13, 36, 46, 53, 97 💬 |
74 | Thalidomide | Fpf 300 (thalidomide) 10件: Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide; Thalidomide (drug); Thalidomide 100mg; Thalidomide 150mg; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide celgene*28cps 50mg; Thalidomide pharmion; Thalidomide, cyclophosphamide and prednisone; | 1件: D00754 D00754 💬 |
1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
002 20件: 2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬 |
75 | Thymosin beta-4 | - | - |
- |
- |
036 2件: 36, 53 💬 |
76 | Tibulizumab | Tibulizumab 2件: Tibulizumab; Tibulizumab (ly3090106); | 1件: D11127 D11127 💬 |
2件: IL17A, TNFSF13B 💬 |
Cytokine-cytokine receptor interaction 7件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis, Th17 cell differentiation |
053 1件: 53 💬 |
77 | Tirabrutinib | Tirabrutinib 1件: Tirabrutinib; | - |
- |
- |
035 3件: 35, 46, 53 💬 |
78 | Tocilizumab | Abatacept, rituximab or tocilizumab 39件: Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra or roactemra); Tocilizumab (actemra); Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab (tcz); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab 162mg/0.9ml sc pfs sc; Tocilizumab 162mg/0.9ml syringe sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab and iv steroids combination; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab iv; Tocilizumab plus methotrexate; Tocilizumab prefilled syringe; Tocilizumab roche; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai); Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs); Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; | 1件: D02596 D02596 💬 |
1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
79 | Tofacitinib | 15n2-tofacitinib 36件: 15n2-tofacitinib; Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib; Tofacitinib (cp-690,550); Tofacitinib (xeljanz); Tofacitinib (xeljanz®); Tofacitinib (xeljanz®) 11mg prolonged release tablet; Tofacitinib 10 mg; Tofacitinib 2 mg; Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; Tofacitinib 5mg po bid; Tofacitinib citate (phase iii formulation); Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate (phase iii formulation); Tofacitinib citrate (proposed commercial formulation - debossed); Tofacitinib citrate (proposed commercial formulation debossed); Tofacitinib citrate (proposed commercial formulation – debossed); Tofacitinib citrate (proposed commercial formulation- debossed); Tofacitinib citrate (proposed commercialformulation - debossed); Tofacitinib citrate cp-690550; Tofacitinib citrate( phase iii formulation); Tofacitinib or baricitinib; Tofacitinib tablet; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Tofacitinibe citrate; | 1件: D09970 D09970 💬 |
4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
011 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬 |
80 | Topramezone | - | - |
- |
- |
006 8件: 6 , 13, 46, 50, 53, 96, 97, 299 💬 |
81 | Ustekinumab | Evaluation of biological predictive factors of clinical response to ustekinumab 36件: Evaluation of biological predictive factors of clinical response to ustekinumab; Group 2 ustekinumab 130 mg; Group 3: ustekinumab approximately 6 mg/kg; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab + mtx (group 2); Ustekinumab + mtx (group 3); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab dose based on bsa and body weight; Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection; | 1件: D09214 D09214 💬 |
3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
037 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬 |
82 | Vitamin A | Dietary supplement: vitamin a 3件: Dietary supplement: vitamin a; Vitamin a; Vitamin ad sig: 1 tablet/tid; | 2件: D00069 D00069
D06543 D06543 💬 |
2件: RARA, RARB 💬 |
Acute myeloid leukemia 8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
013 3件: 13, 53, 90 💬 |
83 | Water | 15 o water 31件: 15 o water; 15-o labeled water; 5% glucose water solution; Behavioral: diet and water adjustment; Behavioral: water tracking; Cholecalciferol concentrate (water-dispersible form); Device: manual toothbrush and water flosser (philips sonicare airfloss); Device: sonic toothbrush (philips sonicare) and water flosser (philips sonicare airfloss); Dextrose, 5% in water; High water intake; Lactose in water; Other: ad libitum water intake; Other: dead sea solar and water treatment; Other: dextrose water 5%; Other: exercise followed cold water immersion; Other: harkány medicinal water; Other: high water intake; Other: potable water; Other: water; Other: water prescription; Pl 12185/0002 & pl 12185/0005(water for injection); Procedure: water exercises; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Sterile water; Sterile water for injection; Sterilised water for injections; Water; Water for injection; Water for injections; Water for injections, ep; | 1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
84 | Xylitol | Xylitol 1件: Xylitol; | 1件: D00061 D00061 💬 |
- |
- |
053 2件: 53, 299 💬 |
85 | Yellow Fever Vaccine | Yellow fever vaccine 2件: Yellow fever vaccine; Yellow fever vaccine (17d); | 1件: D06347 D06347 💬 |
- |
- |
040 7件: 40, 44, 46, 50, 51, 52, 53 💬 |